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Abstract
Introduction: Carotid artery stenting (CAS) is a valid alternative to carotid endarterectomy with 
proper indications. In-stent restenosis (ISR) is a possible complication and there are multiple 
therapeutic options for severe ISR (>70%). The use of drug-eluting balloons (DEB) has increasing 
evidence as a new endovascular treatment for ISR. The authors report a case of recurrent ISR 
treated with a DEB.
Case report: Male patient, 67 years-old, with a history of cervical radiation in 2006. In 2007, he 
had a stroke in the territory of the right internal carotid artery (ICA). The duplex ultrasound 
(DUS) showed right ICA occlusion and left ICA stenosis >70%. He underwent left CAS under À lter 
protection, without complications. He was kept as an outpatient and in 2009 he presented ISR 
>70%. The patient was treated with re-stenting, without residual stenosis and had an uneventful 
course. In 2012, DUS revealed recurrent ISR >70%. Angioplasty with a paclitaxel-eluting balloon 
was performed, with distal cerebral protection, good imaging and hemodynamic results and 
an uneventful course. At 6 months of follow-up, the patient has no complications and no ISR 
documented by ultrasound.
Conclusions: The use of DEB in the treatment of ISR after CAS is an emerging strategy with 
promising results.
© 2013 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Published by Elsevier España, S.L. 
All rights reserved.
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Introduction
Carotid endarterectomy (CEA) is one of the most frequently 
performed vascular surgical procedures to prevent stroke 
associated with carotid stenosis in symptomatic and 
asymptomatic patients.1 It is the best-evaluated surgical 
procedure with an evidence-based medicine level of 1 and 
a recommendation level of A.2 Carotid artery stenting (CAS) 
was initially introduced as an alternative to CEA for high-risk 
patients or patients with hostile neck anatomy (status after 
radiation or previous cervical operations such as neck 
dissection or injury).1,2 The recent AHA/ASA guidelines 
recommend CAS for symptomatic >50% carotid artery 
stenosis and for several patient groups with asymptomatic 
carotid artery stenosis >70%.3
The clinical outcome of CAS is currently under 
investigation and equality of treatment, relative to CEA, has 
not yet been proven. Studies to date comparing the clinical 
outcome of CAS and CEA regarding stroke prevention, 
although large and randomized, have not shown a clear 
noninferiority of CAS to CEA.1 Randomised trials of patients 
with symptomatic carotid stenosis have shown that risk 
of periprocedural stroke is higher with stenting than with 
endarterectomy.4
Despite lack of level 1 evidence from randomized trials, 
the systematic use of cerebral protection appears to have 
reduced neurological complications during CAS, leading to 
consistently better outcomes even in ‘‘high surgical-risk’’ 
patients.5
The occurrence of in-stent restenosis (ISR) after CAS 
ranges from 3% to 20%, with half occurring within the first 
6 months, over a relatively short (up to 2 years) follow-up.2,5-7
The etiology of ISR is still incompletely elucidated, but 
neointimal hyperplasia seems to play a key role in this 
process. Although constant proliferation of smooth muscle 
cells is responsible for deliberate and steady neointimal 
growth, in some cases ISR might have an abrupt course when 
associated with mural thrombus formation.2
The ideal treatment for carotid ISR is yet to be defined. 
Surgical and endovascular treatments have all been used, 
with variable results.6 We report the use of DEB in a patient 
who developed significant recurrent ISR after CAS.
Case report
In October 2007, a 62-year-old man was admitted to our 
department for severe asymptomatic stenosis (>70%) of 
the left internal carotid artery (ICA) and symptomatic 
occlusion of the right ICA, diagnosed by triplex scan. 
He was an ex-smoker and had a past medical history of 
dyslipidemia, hypertension and radiation therapy for larynx 
carcinoma in 2006. He underwent left CAS (Precise stent 
7×40-mm, J&J Cordis) with cerebral protection without 
complications and with good immediate results. He was 
kept as an outpatient, under statin and dual antiplatelet 
therapy. In December 2009, routine ultrasound examination 
of the supra-aortic trunks had shown severe ISR (>70%). The 
patient was treated with re-stenting (two Precise stents of 
8×30-mm + 7×30-mm, J&J Cordis), under filter protection, 
without residual stenosis and uneventful. In 2012, recurrent 
ISR >70% (peak systolic velocity – PSV=453 cm/s) was 
detected at Doppler ultrasound follow-up examination. It 
was decided to perform a DEB angioplasty. The procedure 
was performed through right femoral approach, under 
local anesthesia. The left ICA was engaged in a telescopic 
fashion with a triple coaxial system formed by a 6-F sheath 
and a preloaded 4-F diagnostic catheter over a 0.035-inch 
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Restenose carotídea intra-stent recorrente tratada com drug-eluting balloon: 
caso clínico e revisão da literatura
Resumo
Introdução: O stenting carotídeo (CAS) é uma alternativa válida à endarteriectomia carotídea 
com indicações bem deÀ nidas. A restenose intra-stent (RIS) é uma complicação possível e são 
múltiplas as opções terapêuticas para o tratamento da restenose severa (> 70%). O uso de 
drug-eluting balloons (DEB) tem evidência crescente como nova terapêutica endovascular em 
casos de RIS após CAS. Os autores descrevem um caso clínico de angioplastia com DEB por RIS 
recorrente.
Caso clínico: Doente de 67 anos, submetido a radioterapia cervical em 2006. Em 2007, 
apresentou AVC no território da artéria carótida interna (ACI) direita. O eco-Doppler demonstrou 
oclusão ACI direita e estenose ACI esquerda > 70%. Foi submetido a CAS da ACI esquerda com 
protecção cerebral, sem complicações. Seguido em consulta externa e em 2009 o eco-Doppler 
revelou RIS > 70%. Foi submetido a re-stenting, sem estenose residual e sem intercorrências. Em 
2012, documentada por eco-Doppler recorrência de RIS > 70%. Foi tratado com DEB, sob 
protecção cerebral, com bom resultado imagiológico e hemodinâmico e sem eventos 
neurológicos. O doente apresenta 6 meses de seguimento sem RIS demonstrada por eco-Doppler.
Conclusão: O uso de DEB no tratamento de RIS após CAS é uma estratégia emergente, com 
resultados promissores.
© 2013 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Publicado por Elsevier España, S.L. 
Todos os direitos reservados.
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glidewire. An intravenous heparin bolus (100 U/kg) was 
given after sheath insertion. The 0.035-inch glidewire 
was exchanged for a 0.014-inch coronary wire and then 
the lesion was carefully crossed. Under distal embolic 
protection (Emboshield Abbott) the in-stent lesion was 
predilated using three peripheral artery balloons (Armada 
Abbott 3×40-mm + Armada Abbott 4×40-mm + Viatrac Abbott 
5×20-mm). An over-the-wire paclitaxel-eluting balloon 
(In.Pact Pacific 6×40-mm, Medtronic Invatec) was then 
used. The balloon was inflated at 8 atmospheres for one 
minute and was well tolerated. After the procedure, there 
was no residual stenosis and no angiographic evidence of 
flow-limiting dissection or distal embolization (Fig. 1). The 
patient had an uneventful course and was discharged home 
by day two after DUS that revealed complete hemodynamic 
resolution of the stenosis (PSV=122 cm/s).
Clinical and Doppler ultrasound follow-up was performed 
at 1 and 6 months and shows no related complications and 
no signs of ISR (PSV=128 cm/s).
Discussion
The occurrence of in-stent restenosis (ISR) after carotid 
artery stenting (CAS) ranges from 3% to 20% and varies with 
patient risk factors, lesion characteristics, and the location 
of the stent(s).2,5-7 However, the relatively wide range of 
ISR rates reported in previous studies may be the result 
of different definitions/diagnostic testing for ISR, patient 
selection bias, and length of follow-up.5 
DUS is often used to monitor the patency of the stent and 
the occurrence of ISR. For routine evaluation of unstented 
carotid arteries, DUS is a well validated diagnostic test and 
the cut-off criteria for the different degrees of stenosis are 
clear.8,9 The peak systolic velocity (PSV) is the best predictor 
for the severity of the stenosis.10 However, the degree of 
restenosis in a stented carotid artery, measured according 
to the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) criteria on CTA or MRA, designed for native 
carotid arteries, could be overestimated. The presence 
of a stent increases flow velocities and the reason why 
this happens is not completely clear.1,7,10,11 A possible 
explanation might be pseudoacceleration of the detected 
velocity caused by the stent material interfering with the 
ultrasound signal.1 Another hypothesis has been proposed 
by Nederkoorn et al., who postulate elastic mismatch 
between stented and native areas of the artery.10 Possibly, 
blood flow and blood turbulence behave differently in an 
artificial stent than in a normal vessel and the presence of a 
stent can reduce compliance.7,10 Hakimi et al. reported that 
stent insertion into an ovine carotid artery without stenosis 
caused a 22% increase in the PSV and no change in the 
end-diastolic velocity (EDV). Distal do the in-stent stenosis, 
with moderate stenosis, stent insertion caused a 32% and 
29% increases in the PSV and EDV, respectively; with severe 
stenosis, stent insertion caused a 49% and 56% increases in 
the PSV and EDV, respectively. They concluded by saying 
that stent insertion into an ovine carotid artery without 
stenosis caused a threefold compliance drop compared with 
that measured in the unstented artery.1
The use of an appropriate velocity threshold is central to 
the comparison of restenosis after carotid endarterectomy 
and carotid artery stenting.7 The 70% threshold to define 
high-grade restenosis is the most accepted threshold and has 
been used in the Carotid and Vertebral Artery Transluminal 
Angioplasty Study (CAVATAS), the Stent-Protected 
Angioplasty versus Carotid Endarterectomy (SPACE) trial, 
and the Endarterectomy versus Angioplasty in Patients with 
Severe Symptomatic Carotid Stenosis (EVA-3S) trial.12-14 The 
CREST definition of PSV ≥300cm/s to define >70% ISR was 
based on a comparison of more than 500 duplex ultrasound 
and anatomical comparative imaging studies.15 Several 
A B C D E
 Figure 1 (A) Baseline digital subtraction angiogram of the left internal carotid artery with severe ISR. (B) and (C) Predilatation. 
(D) Paclitaxel-eluting balloon dilation. (E) Completion angiogram showing optimal result at the restenosis site.
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single-institution reports support the use of 300 cm/s or 
more as an appropriate threshold to identify high-grade 
restenosis.1,7,10,16,17
While moderate ISR (50% to 69% by Doppler ultrasound 
or angiography) may be a relatively benign condition 
deserving ‘‘watchful waiting’’ in most cases, significant 
ISR (>70% stenosis) is usually considered an indication for 
revascularization.5 For a long time, it was thought that the 
symptomatology of carotid restenosis was benign.18 Indeed, 
progression to carotid occlusion and embolization and 
occurrence of ipsilateral transient ischaemic attack or 
stroke have been reported.5,7,11,12,15,18
Possible management options for carotid ISR include repeat 
balloon (or cutting balloon) angioplasty, re-stenting, surgical 
approach (CEA with stent removal, carotid artery bypass, 
or interposition graft) and brachytherapy.5,6,19 However, until 
now, there seems not to be a clear preferred treatment 
strategy for ISR and the therapeutic decision is taken on 
a case-by case basis.6,19 Balloon angioplasty and re-stenting 
can be performed with high acute success and low incidence 
of periprocedural complications, but rates of recurrent 
ISR, both early and (mainly) late, have been documented 
in up to 50% of the cases, with a small risk of cerebral 
embolization.5,6 This is a clear indicator of the need for new 
treatment strategies.
Recent evidence in the porcine internal carotid artery 
(ICA) model suggests that implantation of balloon-
expandable drug-eluting stents (DES) may be associated 
with a significant reduction in in-stent neointimal 
hyperplasia compared to the bare metal stents.20 Tekieli et 
al. used the balloon-expandable zotarolimus-eluting stent 
to treat significant ISR after CAS in 7 patients. Despite 
acute favorable results, 1 patient developed symptomatic 
stent occlusion 1 month after the procedure, and another 
patient had a recurrent ISR at 12-month follow-up. In both 
cases, the stent protruding from the distal edge of the 
original stent was deformed and/or kinked.2 Evidence is 
accumulating to support the effectiveness of drug-eluting 
balloons (DEBs) as a new endovascular strategy for ISR 
treatment.5 While encouraging results have been reported 
in coronary arteries, limited data exist about the use of 
DEB to treat ISR in peripheral arteries.21-25 Indeed, only 
a few patients with ISR were enrolled in 2 randomized 
studies (22/154 in the THUNDER trial and 6/87 patients in 
the FemPac trial) comparing DEB vs. standard treatment, 
hampering conclusions about safety and efficacy.23,24 Vajda 
et al. recently reported DEB treatment of intracranial 
stent restenosis in 51 patients. Compared to conventional 
balloons, the ISR recurrence rate was significantly 
lower with DEB (9% vs. 50%) at 8-month follow-up, with 
a favorable clinical outcome.25 Specifically, there are 
no data on both safety and long-term results of DEB in 
patients with ISR after CAS. Montorsi et al. reported 
paclitaxel-eluting balloon treatment in 7 patients with ISR 
after CAS. Technical/procedural success was achieved in 
all cases and angiographic stenosis decreased from 83±5% 
to 18±6%. At 6 and 12 months, PSVs after DEB treatment 
were significantly lower compared to those assessed 
at comparable intervals after CAS and they had no ISR 
recurrence by Doppler ultrasound at a mean follow-up of 
13.7 months. They concluded by saying that the significantly 
lower mean PSV after DEB compared to following stent 
implantation may indicate a substantial antiproliferative 
effect of the paclitaxel-coated balloon.5 
Another concern is whether cerebral protection is really 
needed in patients undergoing endovascular treatment for 
ISR. Reimers et al. retrieved macroscopic debris in 71% of 
the examined filters in a large series of carotid ISR patients 
treated with angioplasty after CAS.26 Moreover, it has been 
shown that carotid ISR occurring after 24 to 36 months is 
often due to new atherosclerotic plaque formation rather 
than neointimal proliferation, increasing the embolization 
risk during balloon dilation to a level similar to that reported 
for CAS of de novo carotid artery stenosis.5,18 For these 
reasons, cerebral protection seems to be advisable when 
treating ISR.
Final technical issues refers to sizing of DEBs, duration 
of inflation and predilatation. A properly sized DEB 
plays an important role in achieving effective delivery of 
the antiproliferative drug within the vessel wall.5 The 
recommendations for DEB use in coronary ISR include 
predilation with a conventional balloon, DEB sizing according 
to a 0.8– 1:1 balloon-to-vessel ratio, and a single inflation 
at nominal pressure (8 atmospheres).5 Medtronic’s In.Pact 
system has a natural coating that reduces the total drug 
elution time to 30 to 60 seconds; the majority of the drug 
is released within the first 30 seconds. The total drug load 
depends on both size and length of the balloon.6 DEBs might 
be useful mainly to treat diffuse, proliferative restenosis, 
while a potential use for predilation of long, calcified 
lesions (at high risk of stent fracture and restenosis) could 
be anticipated. Additionally, the possibility of routine 
predilation with DEB in the restenosis-prone intracranial 
circulation must be considered.6
Conclusion
There is increasing evidence for effectiveness of DEB 
angioplasty in the treatment of coronary and peripheral 
arteries, where the use of DEB (vs. conventional non-coated 
balloons) has been shown to reduce the restenosis 
rate.2 Data observed in other arterial beds was the rational 
for the application of DEB in the management of carotid ISR, 
that is emerging as a promising strategy with encouraging 
early and midterm results.5,6
Significant advantages of DEBs include fast, homogeneous 
release of a high dose of drug and absence of a permanent 
foreign body and polymeric material. Potential limitations of 
DEBs are the acute elastic recoil typical of balloon angioplasty 
and the variability of pharmacokinetics.6 Paclitaxel is the 
primary drug for DEB technology because of its potent 
antiproliferative effect and prolonged tissue retention.6
Further evidence in the form of randomized controlled 
trials is required to confirm whether DEBs are superior to 
other treatment options of post-CAS ISR.5
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